Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Introduction/Background Anti-VEGF Dosing Regiments: Review of the Pertinent Studies Comparing the Anti-VEGF Dosing Strategies Conclusions References While ...

Kalaris Therapeutics, Inc. has completed its merger with AlloVir, positioning itself to advance the development of TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Age-related macular degeneration (AMD) can cause vision loss. Learn about AMD, the importance of diversity in clinical trials.

images from the Early Detection of Neovascular AMD study were recently reanalyzed for the double-layer sign and 2 other OCT biomarkers, assessing their ability to predict progression to exudative ...

There still remain several unanswered questions regarding exudative AMD treatment regimens, including the interval by which "treat and extend" protocols should be extended at each visit ...